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TDP-43 as a potential biomarker for
amyotrophic lateral sclerosis: a systematic
review and meta-analysis
Vivek Majumder1†, Jenna M. Gregory1,2*† , Marcelo A. Barria3, Alison Green3 and Suvankar Pal1,2,3*
Abstract
Background: Frontotemporal dementia (FTD) and Amyotrophic Lateral Sclerosis (ALS) are incurable, progressive
and fatal neurodegenerative diseases with patients variably affected clinically by motor, behavior, and cognitive
deficits. The accumulation of an RNA-binding protein, TDP-43, is the most significant pathological finding in
approximately 95% of ALS cases and 50% of FTD cases, and discovery of this common pathological signature,
together with an increasing understanding of the shared genetic basis of these disorders, has led to FTD and ALS
being considered as part of a single disease continuum. Given the widespread aggregation and accumulation of
TDP-43 in FTD-ALS spectrum disorder, TDP-43 may have potential as a biomarker in these diseases.
Methods: We therefore conducted a systematic review and meta-analysis to evaluate the diagnostic utility of
TDP-43 detected in the cerebrospinal fluid (CSF) of patients with FTD-ALS spectrum disorder.
Results: From seven studies, our results demonstrate that patients with ALS have a statistically significantly higher
level of TDP-43 in CSF (effect size 0.64, 95% CI: 0.1–1.19, p = 0.02).
Conclusions: These data suggest promise for the use of CSF TDP-43 as a biomarker for ALS.
Keywords: TDP-43, Amyotrophic lateral sclerosis, Biomarker, Systematic review, Meta-analysis
Background
Frontotemporal dementia (FTD) is an umbrella term for a
spectrum of neurodegenerative disorders. These disorders
primarily affect behaviour, personality, executive function
and language (and may include motor impairment). It is
the second most common form of dementia after Alzhei-
mer’s disease (AD) in people under 65 years old, with the
average age of onset being between 45 and 65 years old,
and the peak prevalence being around age 65 to 69 [1].
Prognosis is poor with a median survival of 8–10 years
and a steady rate of decline [2]. Currently, there are no
curative or disease modifying treatments (DMT) available,
so patients are treated symptomatically [3].
FTD also affects the motor system and is now increas-
ingly thought to be on a syndromic spectrum with
amyotrophic lateral sclerosis (ALS; [4]). ALS is a
neurodegenerative disease, and has a heterogeneous pres-
entation affecting motor function, eventually affecting the
ability to speak, swallow and breathe [5]. It affects both
upper and lower motor neurons, but tends to spare sensory
neurons. Sporadic cases of ALS have a peak incidence at
around 60 years old, whereas familial cases peak at 43–
52 years old. Familial cases make up 10–20% of cases [5].
Crucially, approximately 50% of patients exhibit changes in
behaviour and cognition [1, 5–7], with up to 15% develop-
ing FTD [8–10]. Median survival from disease onset is
3.5 years and from diagnosis is 2 years [8], though 5–10%
of patients can survive up to 10 years or more [6]. Riluzole,
a sodium channel blocker which may also have other
effects through inhibition of NMDA receptor signaling,
glutamate release and uptake, is the only licensed DMT for
ALS, and has been demonstrated to prolong life by 3–
4 months [11]. There have been recent reports suggesting
efficacy of Edaravone and Masitinib as additional treat-
ments but these drugs have yet to receive widespread
licensing. Mean time to diagnosis is 15 months [8] from the
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onset of first symptoms (ranging from 5 to 24) and relies
on clinical evaluation, supported by examination and
electromyography. This long diagnostic delay reflects the
diagnostic challenge faced when assessing patients with a
clinically heterogeneous and progressive neurodegenerative
disease. The lack of robust biomarkers and diagnostic tests
to support an accurate diagnosis further compounds this
diagnostic challenge. The identification of biomarkers will
enable early and accurate diagnosis thus avoiding unneces-
sary investigations and enable rapid stratification of patients
into clinical trials. There are currently no biomarkers for
FTD or ALS.
A substantial monogenetic component to these diseases
has recently been established. The most frequent genetic
abnormality is an intronic hexanucleotide repeat expansion
in the gene that codes for C9orf72, found to be present in
the majority of cases of familial cases of FTD-ALS
spectrum disorders [4, 6]. Pathological assessment of
specific brain regions of these cases at post-mortem reveals
characteristic immuno-histochemical staining patterns of
abnormally phosphorylated TDP-43 in cytoplasmic inclu-
sion (particularly in the motor cortex, spinal cord and the
frontal and temporal lobes) and p62 accumulation (particu-
larly in the granule cell layer of the cerebellum and in the
dentate gyrus of the hippocampus). In 2006, TDP-43 was
identified as the main pathological finding in most sporadic
and familial cases of both ALS and FTD [12]. TDP-43 is a
protein with multiple functions, but is primarily involved in
alternative splicing and transcriptional regulation [6]. In
FTD and ALS, TDP-43 becomes ubiquinated, hyperpho-
sphorylated and C-terminally truncated, increasing its ag-
gregation propensity and causing widespread neurotoxicity
and cell death [1]. Given the high burden of TDP-43 accu-
mulation in the central nervous system of the majority of
patients with FTD-ALS spectrum disorder, TDP-43 has
been postulated as a biomarker in this disease.
A pathological diagnosis (rather than a clinical diagnosis)
of FTD is referred to as frontotemporal lobar degeneration
(FTLD). Indeed, three major pathological subtypes of FTLD
exist characterized by the type of pathology observed in
post-mortem tissue. FTLD- tau, FTLD-FUS and FTLD-TDP.
These molecular subtypes are characterized respectively by
the accumulation of misfolded tau, FUS and TDP-43 intra-
cellular inclusions [13]. Due to the increasing prevalence of
DMTs targeting specific molecular mechanisms there is an
increasingly emergent need for biomarkers to distinguish
between these subtypes. A potential biomarker, such as CSF
TDP-43 could have the potential to predict the neuropatho-
logical diagnosis and thus provide us, not only with a diag-
nostic biomarker, but also a biomarker to enable
stratification for targeted DMT development.
The aims of this study are to systematically review all
studies analysing CSF TDP-43 concentrations in FTD and
ALS patients and conduct a meta-analysis to investigate
whether there is a significant difference between concentra-
tions of CSF TDP-43 in patients with FTD-ALS spectrum
disorders compared to neurological and non-neurological
controls. Our hypothesis is that CSF TDP-43 will be
significantly increased in patients with FTD-ALS spectrum
disorders compared to controls.
Methods
Objectives
Population
Clinical studies of patients with FTD-ALS spectrum
disorder (ALS, FTD, and FTD-ALS).
Intervention
CSF TDP-43 detected by ELISA or western blot.
Comparison
Control patients who are 1) Neurological controls
(diagnosed with non-dementia neurological conditions),
or 2) Non-neurological controls (diagnosed with a
non-neurological condition or healthy).
Outcome measure
Primary outcome: effect size (concentration of TDP-43
in CSF of in FTD-ALS, FTD and ALS patients compared
to controls). Secondary outcomes: Assessment of quality
and heterogeneity between studies.
Study design
All study types where CSF TDP-43 concentrations were
measured and compared to a control.
Search methods
Sources
Databases: 1. PubMed, 2. Medline, 3. EMBASE 4. LILACs
5. IMEMR 6. WPRIM 7. Chinese Science Citation Index.
The date of searches was 01/03/17 and there were no
publication date restrictions and no language restrictions.
Search terms
(Frontotemporal Lobe Dementia [MeSH] OR
Amyotrophic Lateral Sclerosis [MeSH] OR Motor Neuron
Disease [MeSH]) AND (Cerebrospinal Fluid [MeSH] OR
Lumber Puncture [MeSH]) AND TDP [MeSH]
Screening
The title and abstract of each paper were screened for
relevance with respect to inclusion and exclusion
criteria. For studies meeting our predefined criteria the
full text was retrieved, imported to Excel and duplicate
records were discarded. The quality of each paper was
then evaluated by the QUADAS-2 quality score and
relevant data were extracted.
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Eligibility
Inclusion criteria
 All studies that measure TDP-43 in the CSF of living
patients with ALS or FTD, compared to controls.
Exclusion criteria
 No control group
 Animal studies
 Post mortem studies
 Reviews
 Letters and comments
 Abstracts
 Non-parametric results (Meta-Analysis only)
Study characteristics to be extracted:
 Study ID: (i) Author and (ii) Year
 Intervention: FTD (behavioural, non-fluent or
semantic), ALS or both (FTD-ALS)
 Medical diagnosis of comparison/controls
 Intervention quantification method
(western blot or ELISA)
 Age: mean age of patients and controls
 Sex: of patients and controls
 Diagnosis method of patients
 Genetic factors
 Sample size: of patients and controls
Further searches
Two similar searches were done, with the similar objec-
tives. These were to look at the effect size of lympho-
cytic bound TDP-43 in FTD, ALS and FTD-ALS
patients compared to controls, and the effect size of
plasma TDP-43 in FTD, ALS and FTD-ALS compared
to controls. However, neither of these searches produced
enough papers in order to do a systematic review.
Search terms
(Frontotemporal Lobe Dementia [MeSH] OR Amyotrophic
Lateral Sclerosis [MeSH] OR Motor Neuron Disease
[MeSH]) AND (Lymphocyte [MeSH] OR White Cell
[MeSH] or White Blood Cell [MeSH]) AND TDP [MeSH].
(Frontotemporal Lobe Dementia [MeSH] OR Amyo-
trophic Lateral Sclerosis [MeSH] OR Motor Neuron
Disease [MeSH]) AND (Plasma [MeSH] OR Serum
[MeSH] OR Blood [MeSH]) AND TDP [MeSH]
Statistical analysis
An individual meta-analysis was carried out for each
group of patients (i) FTD alone, (ii) ALS alone and (iii)
FTD and ALS patients combined as an overall evaluation
of FTD-ALS spectrum disorders. Additional subgroup
analyses included: an assessment of heterogeneity and a
quality score. Outcome measures were calculated for each
of the studies identified and included on a forest plot.
Given the variability of intervention quantification in-
cluded in the analysis, outcome measures were recorded
in standardised mean differences (SMD), to allow for
meaningful comparisons between studies. SMD was com-
pared using Hedges g-statistic, to account for bias from
small sample sizes, using a random effects model. SMDs
were reported as odds ratios with 95% confidence inter-
vals. Heterogeneity was assessed for all outcome measures
using I2-values, and a funnel plot and Egger’s regression
test was used to assess publication bias.
Results
Systematic review reveals poor reporting of measures to
reduce bias but no evidence of publication bias
Overall, 6 studies were identified for meta-analysis, including
a total of 274 participants [14–19], 150 neurological controls
(Table 1) and 146 patients with FTD-ALS spectrum disor-
ders (94 with ALS and 77 with FTD) (Fig. 1a). Seven studies
were included in the qualitative analysis (Table 1; Fig. 1a).
The data from the Suarez-Calvet et al., 2014 study [20] was
non-parametric, so could not be compared to the other
studies in the quantitative analysis. There was no evidence
of publication bias detected by Egger’s regression (best-fit
gradient of − 0.01017 ± 0.03182 and p= 0.8029) or funnel
plot. Systematic review, risk of bias and quality assessment
revealed that only 3 of the 7 identified papers reported on
measures to reduce bias, such as blinding (Table 1). FIve of
the studies used an ELISA technique to evaluate the con-
centration of TDP-43 in CSF samples [14–18] with the
remaining two papers using a semi-quantitative analysis of
immunoblot intensity. Suarez-Calvet et al., 2014 report con-
centrations as an ELISA comparison, with a manufactured
TDP-43 standard. Steinacker et al., 2008 used an immuno-
blot intensity comparison between samples and a stock sam-
ple of CSF TDP-43 from the post mortem frontal lobe of a
single FTD patient, which increases the risk of bias due to
the semi-quantitative nature of immunoblotting. Four of the
7 studies were assessed as having a low risk of bias as deter-
mined by QUADAS-2 quality assessment (Table 1; [14–16,
19]) and 2 studies were assessed to have a risk of bias due to
lack of blinding [17, 18]. The control populations used were
different between studies, 2 studies used healthy controls
[19, 20] and 4 used non-neurodegenerative neurological pa-
tients as controls [14, 16–18] with conditions such as focal
complex seizures or depression. Kasai et al., used a combin-
ation of non-neurodegenerative neurological patients and
healthy controls. All studies used an appropriate clinical
diagnosis to confirm the diagnosis of ALS or FTD. Two
studies used additional, supportive diagnostic modalities
such as fMRI or post mortem lab testing [14, 18].
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Meta-analysis reveals a statistically significant increase in
TDP-43 in the CSF of FTD-ALS and ALS patients, but not
FTD patients alone
We conducted three separate meta-analyses of the in-
cluded studies to evaluate the potential of CSF TDP-43
as a biomarker in each of (i) FTD-ALS spectrum disor-
ders (ALS and FTD combined), (ii) FTD alone, and (iii)
ALS alone. Meta-analysis of FTD-ALS spectrum disor-
ders versus controls using standard mean difference
found an effect estimate of 0.55 (95% CI: 0.01–1.09) and
a Z-score of 2.0 (p < 0.05) demonstrating a significant in-
crease in detectable TDP-43 in the CSF of patients with
FTD or ALS compared to controls. However, Chi2 was
20.57 and I2 was 76% showing significant heterogeneity
in this dataset (Fig. 1b). Meta-analysis of studies asses-
sing TDP-43 in the CSF of patients with FTD alone
showed an effect estimate of 0.50 (95% CI: -0.65 - 1.65;
Fig. 1c), although this favours increased levels of
TDP-43 in the control group, this finding does not reach
statistical significance with a Z-score of 0.85 (p = 0.40).
There was a similarly significant heterogeneity with a
Chi2 of 10.75 and an I2 of 81%. Meta-analysis of studies
assessing TDP-43 in the CSF of patients with ALS alone
showed an effect estimate of 0.64 (95% CI: 0.10–1.19). A
Z-score of 2.3 (p = 0.02) showing a significant increase in
detectable TDP-43 in the CSF of ALS patients. Chi2 was
11.80 and I2 was 66% showing moderate heterogeneity
(Fig. 1d).
Discussion
To our knowledge, this is the first systematic review and
meta-analysis of the literature assessing the utility of
TDP-43 in the CSF of patients with FTD-ALS spectrum
disorders as a potential diagnostic biomarker. We have
shown that CSF TDP-43 is significantly increased in pa-
tients with FTD-ALS spectrum disorder. However, when
analysing patients with ALS and FTD separately, only
patients with ALS (not patients with FTD) showed a sig-
nificantly increased CSF TDP-43. We also detected sub-
stantial heterogeneity and relative risk of bias in these
studies. This heterogeneity is likely due to the wide var-
iety of methods used to analyse CSF TDP-43 concentra-
tions, but could also reflect the disease heterogeneity
(both clinically and genetically) seen in these spectrum
a b
c
d
Fig. 1 a PRISMA Diagram detailing each step of the systematic review, with number of studies highlighted as n = x. Reasons for exclusion given in
boxes on the right. b Forest plot assessing the utility of CSF TDP-43 as a biomarker for FTD-ALS displaying standardised mean differences (SMD) and
95% confidence intervals (CI) using a random effects model. Study identifiers (author and year of publication) given on left. Heterogeneity calculated
using Chi2 and I2 showing significant heterogeneity. Summary statistic (black diamond shows statistically significantly higher TDP-43 in the CSF of FTD-
ALS patients compared to controls. c Forest plot assessing the utility of CSF TDP-43 as a biomarker for FTD displaying SMD and 95% CI using a
random effects model. Study identifiers (author and year of publication) given on left. Heterogeneity calculated using Chi2 and I2 showing significant
heterogeneity. Summary statistic (black diamond shows no statistically significant difference in TDP-43 in the CSF of FTD patients compared to
controls. d Forest plot assessing the utility of CSF TDP-43 as a biomarker for FTD-ALS displaying SMD and 95% CI using a random effects model. Study
identifiers (author and year of publication) given on left. Heterogeneity calculated using Chi2 and I2 showing significant heterogeneity. Summary
statistic (black diamond shows statistically significantly higher TDP-43 in the CSF of ALS patients compared to controls
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disorders and the heterogeneity of controls used for com-
parison. Two of the studies used normal healthy controls
[19, 20] whilst the remaining included patients with a wide
variety of neurological diagnoses as controls. Kuiperij et al.
excluded patients with non-FTD-ALS motor deficits, mean-
ing their data could attenuate the effect size of FTD-ALS
spectrum and pure FTD patients in this meta-analysis,
therefore increasing heterogeneity. Steinacker et al. com-
pared their concentration of TDP-43 to a standard devel-
oped from a single patient with FTD. There is no indication
of how representative this patient is compared to other
FTD-ALS spectrum disorder patients and depending on the
concentration of TDP-43 in their standard, this could affect
the final reported TDP-43 concentrations. Risk of bias could
also have had an impact on the heterogeneity seen. For ex-
ample, neither Feneberg et al. nor Suarez-Calvet et al. com-
mented on blinding in their methods, an important aspect
of scientific rigor to ensure that all samples are treated and
assessed equally, limiting the potential for bias. Further-
more, variation in time from sampling to storage, from
30 min to several hours (and in 5 out of 7 studies, this time
was not documented), post CSF sampling may influence
TDP-43 quantification due to protein degradation. Diagnos-
tic criteria for patient identification did not vary between
studies, all but two studies used the El Escorial criteria for
ALS and all studies studying FTD used Consensus Criteria
for FTD, and many of the studies went to further investigate
a diagnosis of FTD, ALS or FTD-ALS by with more detailed
imaging studies or post mortem [18].
Given the significant effect size shown in this
meta-analysis, demonstrating an increase in the levels of
detectable TDP-43 in patients with ALS, further research to
refine the use of CSF TDP-43 as a diagnostic tool is war-
ranted. Furthermore, a longitudinal study of CSF TDP-43
concentrations in patients with FTD-ALS spectrum disor-
ders might show if CSF TDP-43 increases with disease pro-
gression. Similarly, a longitudinal study investigating
carriers of the C9orf72 hexanucleotide expansion might
provide an indication as to how early TDP-43 aggregation
occurs, and potentially would allow us to diagnose
FTD-ALS spectrum disorders pre-symptomatically in these
patients [4, 7, 21]. This would facilitate study of preventa-
tive and disease modifying interventions in early disease.
However, given the wide range of techniques used to evalu-
ate the concentration of TDP-43 in FTD-ALS spectrum
disorder patients there clearly needs to be agreement with
regards to consistency of sampling, storage and testing
techniques, with a standardized operating protocol adhered
to by all diagnostic laboratories. Ideally, a larger, much
more highly powered study into the effect of CSF TDP-43
as a diagnostic tool for FTD-ALS spectrum disorders would
be done. This study should have aged-matched controls
and ALS, FTD and crucially FTD-ALS patients (patients
with both ALS and FTD symptoms), with the controls
having no neurological or psychiatric morbidity and the pa-
tients having no confounding co-morbidities or genetic var-
iations (such as C9orf72) that might skew data. The study
should be carried out longitudinally in order to map the
progression of TDP-43 in both controls and patients. Diag-
nosis would be done using currently approved diagnostic
tools, with post-mortem pathological verification of diagno-
sis. Both the sampler and the pathologist should be blinded
to whether the CSF is from a control or a patient. Equally,
analysis should be done with an ELISA and presented in
empirical concentrations to improve transparency. As of yet,
there are not enough studies into the TDP-43 in the blood,
either in lymphocytes or in plasma. However, these are ave-
nues for future meta-analyses (given more studies), as they
provide less invasive diagnostic tests than lumbar puncture.
Study limitations
Our data demonstrate a significant difference in TDP-43
levels in ALS patients compared to controls, implying that
CSF TDP-43 levels show promise as a potential biomarker
in ALS. It is probable that the statistically significant result
observed in FTD-ALS spectrum disorder cases (Fig. 1b),
could be due to the ALS patients included therein as FTD
patients alone did not show a statistically significant increase
in CSF TDP-43. This is likely reflected in the substantial het-
erogeneity seen in the combined analysis. However, whilst
the lower confidence interval for FTD alone cases does inter-
sect the line of no effect, the effect size and upper confidence
interval are still favouring a higher level of TDP-43 in cases
compared to controls, indicating that further studies are war-
ranted to reduce the confidence intervals sufficiently to as-
certain the potential of TDP-43 as a biomarker in FTD.
Furthermore, whilst TDP-43 pathology is a unifying feature
of the majority of ALS and FTD cases, TDP-43 accumula-
tion is also observed in other neurodegenerative conditions;
including but not limited to AD. Whilst our findings suggest
that CSF TDP-43 may be a promising biomarker in ALS, it’s
potential in the context of other neurodegenerative condi-
tions is not yet fully understood. There are currently only
two publications assessing the utility of TDP-43 as a bio-
marker in AD [22, 23], which we considered to be too small
a sample to conduct a meta-analysis on. However, future sys-
tematic reviews should consider including an assessment of
TDP-43 in other neurodegenerative diseases when these data
become available.
Conclusion
Our systematic review and meta-analysis reveals early sup-
portive data indicating that TDP-43 detected in the CSF of
patients with FTD-ALS spectrum disorders in particular
ALS patients could be a promising biomarker in these dis-
eases. Given the current paucity of diagnostic and prognos-
tic biomarkers in these disorders, this result clearly
indicates that further studies in to its utility are warranted.
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